Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.
If you are researching adipose-derived stem cell therapy in Japan, you will quickly notice that the country has a dedicated legal framework for regenerative medicine. For international patients, this framework can feel unfamiliar. This article explains, in plain language, how Japan’s regulatory system relates to adipose stem cell therapy and which questions are worth bringing to a doctor. It is general information, not medical advice, and it cannot replace a consultation.
In short: in Japan, regenerative treatments that use cultured cells are expected to be provided under a legally reviewed plan, with defined roles for the clinic and the cell processing facility. Understanding this structure helps you ask better questions before you decide anything.
Why Japan Regulates Regenerative Medicine Separately
Japan treats regenerative medicine as its own category. The Act on the Safety of Regenerative Medicine, usually shortened to the ASRM, was introduced to allow medical institutions to offer regenerative treatments while setting rules for how they are planned, reviewed, and reported. The aim is to balance patient access to emerging therapies with oversight of the people and facilities that handle living cells.
The Act classifies regenerative medicine by risk level, and the review process depends on the category. A clinic that wishes to offer a treatment must prepare a plan describing what will be done, how cells will be handled, and what risks are anticipated. That plan is reviewed by a certified committee and submitted to the Japanese authorities before treatment can be provided.
What a Provision Plan Means for Adipose Stem Cell Therapy
Adipose-derived stem cell therapy involves collecting a very small amount of your own fat tissue, culturing the mesenchymal stem cells it contains at a specialized facility, and returning the cells by intravenous infusion. Because cells are processed outside the body, the treatment falls within the scope of Japan’s regenerative medicine rules.
Grand Green Osaka Umekita Clinic describes this therapy as being provided under a regenerative medicine provision plan in accordance with Japanese law. In practical terms, a provision plan is the document that sets out the treatment’s content, the facilities involved, the way patients are informed, and how problems would be handled. It is not a statement that a treatment works for any particular person, and it does not remove the need for individual medical judgment.
When you read about any clinic’s regenerative offering, it is reasonable to ask whether the specific treatment you are considering is covered by a provision plan, and what that plan covers.
The Roles of the Clinic and the Cell Processing Facility
Under the Japanese system, the medical institution and the cell processing facility have separate responsibilities. The clinic examines the patient, explains the treatment, collects the fat tissue, and performs the infusion. The processing facility handles the cells during culture and expansion, following documented procedures.
This division of roles is one reason patients are encouraged to ask about documentation and communication. For example, you may wish to ask how your cells are identified throughout the process, how the clinic is informed of quality checks, and what happens if a batch does not meet the required standards. A good consultation should give you clear, understandable answers rather than general reassurance.
This Is a Self-Pay Treatment, and Evidence Is Still Developing
Adipose stem cell therapy at our clinic is a self-pay (non-insured) treatment, which means it is not covered by Japan’s public health insurance. Costs, number of visits, and timelines are confirmed by a doctor after an examination, so it is wise to request a written explanation before making a decision.
It is also important to be realistic about the evidence. Research into mesenchymal stem cells, including studies indexed on PubMed, continues to grow, and some laboratory and clinical reports describe anti-inflammatory and tissue-supporting properties. However, results differ between studies, conditions, and individuals, and a regulatory framework does not by itself prove that a therapy will help you. Stem cell therapy is not a replacement for standard medical care, and nobody can promise a particular outcome.
Questions to Prepare Before Your Consultation
A short list of questions can make a first appointment more productive, especially if you are traveling from overseas and have limited time in Osaka:
- Is the treatment I am considering covered by a regenerative medicine provision plan, and can I see a summary in a language I understand?
- Which facility will process my cells, and what quality checks are carried out?
- What are the possible risks and side effects, and how would they be managed?
- Which conditions or health histories might make this treatment unsuitable for me?
- What is the total cost, and what is and is not included?
- How many visits are needed, and what follow-up is possible if I return to my home country?
Bring your medical records, a list of current medications, and any imaging or test results from your own doctor. These help the physician decide whether the treatment is appropriate at all.
Getting Information in Your Language in Osaka
Grand Green Osaka Umekita Clinic is located in the Umeda area of Osaka, which is easy to reach from Kansai International Airport and from major rail lines. The clinic provides an information page for international patients, and you can use it to learn about the flow of treatment, fees, and frequently asked questions before you contact the clinic.
If you are considering medical travel, it can help to start by reading the adipose-derived stem cell therapy page and the international patients page, then writing down your questions. A consultation with a doctor is the step where your own history, goals, and suitability are discussed. Whether to proceed is always your decision, and it is perfectly reasonable to take time, compare options, and speak with your regular physician first.
- 1Learn the lawJapan's regenerative rules
- 2Check the planProvision plan coverage
- 3Prepare questionsRisks, costs, visits
- 4Doctor consultationIndividual suitability
This figure is a conceptual diagram that summarizes the article's content
References
Supervising Physician
Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic
Hidenori Shimada
Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.
* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.